GeneDx Holdings Corp. (WGS), a healthcare company, on Monday reported net loss in the fourth quarter despite higher revenue compared with the previous year.
For the fourth quarter, net loss came in at $17.67 million from $5.44 million in the previous year.
Loss per share were $0.61 versus $0.18 last year.
Adjusted net income decreased to $4.40 million from $17.45 million in the prior year.
Adjusted earnings per share were $0.14 versus $0.59 last year.
Loss from operations came in at $14.24 million compared with profit of $8.81 million from
Revenue increased to $120.99 million from $95.64 million in the previous year.
Further, the company reaffirms full-year 2026 revenue guidance of $540 million to $555 million and adjusted net income to be positive for the year.
In the pre-market trading, GeneDx is 3.58% higher at $85 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.